Tudor Investment Corp ET AL Purchases 25,645 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

Tudor Investment Corp ET AL grew its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 21.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 146,667 shares of the medical instruments supplier’s stock after purchasing an additional 25,645 shares during the quarter. Tudor Investment Corp ET AL owned about 0.25% of Merit Medical Systems worth $14,186,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC bought a new position in Merit Medical Systems during the 4th quarter worth approximately $889,000. Nebula Research & Development LLC boosted its position in shares of Merit Medical Systems by 114.7% during the 4th quarter. Nebula Research & Development LLC now owns 9,319 shares of the medical instruments supplier’s stock worth $901,000 after purchasing an additional 4,979 shares in the last quarter. Oberweis Asset Management Inc. boosted its position in shares of Merit Medical Systems by 3.3% during the 4th quarter. Oberweis Asset Management Inc. now owns 208,760 shares of the medical instruments supplier’s stock worth $20,191,000 after purchasing an additional 6,620 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its position in shares of Merit Medical Systems by 2.3% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,633,246 shares of the medical instruments supplier’s stock worth $157,968,000 after purchasing an additional 36,489 shares in the last quarter. Finally, Susquehanna International Group LLP boosted its position in shares of Merit Medical Systems by 210.5% during the 4th quarter. Susquehanna International Group LLP now owns 34,951 shares of the medical instruments supplier’s stock worth $3,380,000 after purchasing an additional 23,695 shares in the last quarter. Institutional investors own 99.66% of the company’s stock.

Merit Medical Systems Trading Up 0.9 %

Shares of MMSI stock opened at $95.44 on Tuesday. The stock has a market capitalization of $5.64 billion, a PE ratio of 46.78, a P/E/G ratio of 2.34 and a beta of 0.85. Merit Medical Systems, Inc. has a 1-year low of $73.67 and a 1-year high of $111.45. The business has a 50-day moving average of $98.38 and a 200 day moving average of $100.61. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.11. The business had revenue of $355.35 million during the quarter, compared to analysts’ expectations of $352.57 million. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The business’s revenue was up 9.8% on a year-over-year basis. During the same quarter last year, the business posted $0.77 EPS. As a group, sell-side analysts anticipate that Merit Medical Systems, Inc. will post 3.37 earnings per share for the current year.

Insider Activity at Merit Medical Systems

In other news, Director Stephen C. Evans sold 5,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $105.31, for a total value of $526,550.00. Following the transaction, the director now owns 4,657 shares in the company, valued at $490,428.67. This represents a 51.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Brian G. Lloyd sold 25,000 shares of the stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $99.50, for a total transaction of $2,487,500.00. Following the completion of the transaction, the insider now owns 38,993 shares in the company, valued at $3,879,803.50. This trade represents a 39.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 109,132 shares of company stock valued at $11,139,521 in the last 90 days. Corporate insiders own 3.70% of the company’s stock.

Analyst Ratings Changes

MMSI has been the topic of a number of research analyst reports. Canaccord Genuity Group cut their price objective on shares of Merit Medical Systems from $127.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday. JPMorgan Chase & Co. assumed coverage on shares of Merit Medical Systems in a report on Friday, March 28th. They issued an “overweight” rating and a $120.00 target price on the stock. Robert W. Baird lowered their target price on shares of Merit Medical Systems from $111.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday. Wells Fargo & Company set a $106.00 target price on shares of Merit Medical Systems and gave the stock an “overweight” rating in a report on Friday. Finally, Piper Sandler lowered their target price on shares of Merit Medical Systems from $116.00 to $112.00 and set an “overweight” rating on the stock in a report on Wednesday, April 23rd. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $107.78.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.